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ABSTRACT
Graft-versus-host disease (GVHD) is a cause of serious morbidity and mortality in >50% of recipients of
unrelated hematopoietic stem cell transplantation (HSCT). We performed a trial using Campath 1 H pre- and
post-HSCT in an attempt to decrease the incidence of GVHD without increasing the risk of infection or
relapse. Patients were retrospectively compared to a population of patients who received antithymocyte
globulin (ATG) pre- and post-HSCT. Twenty-seven patients were evaluated for this study. Fourteen patients
received Campath 1H and 13 patients received ATG. Demographics of patients who received Campath 1H
consisted of 9 males and 5 females, with a median age of 13 years (3-17.8 years). Thirteen patients received
unrelated bone marrow and 1 patient received unrelated PBSC. Demographics of patients receiving ATG
consisted of 9 males, 4 females with a median age of 7.4 years (21 months-19 years). Twelve patients received
unrelated bone marrow and 1 patient received unrelated PBSC. Diagnoses were similar between the 2 groups.
Patients who received Campath1H received a total dose of 52 mg/m2 pre-HSCT and 20 mg/m2 post-HSCT.
Patients who received ATG received a total dose of 60 mg/kg pre-HSCT and 100 mg/kg post-HSCT. GVHD
prophylaxis and supportive care measures were similar in both groups, including aggressive antimicrobial
therapy. There was a significant difference in the incidence of severe (grade III and grade IV) GVHD between
the 2 groups (Campath [0 of 14] versus ATG [6 of 13], P  .006). Among the patients who were transplanted
for leukemia, there was no significant difference between the 2 groups in terms of relapse (Campath [2 of 14]
versus ATG [4 of 9], P  0.16). The 100-day survival between the 2 groups was not significantly different.
Patients receiving Campath 1H had the presence of CD3T cells (>30 cells/mL) in their peripheral blood later
than in those who received ATG (64.5 days [Campath 1H] versus 27days [ATG], P  .001). The median time
to the development of a normal PHA response occurred later in the Campath 1H arm (283 days[(Campath 1H]
versus 88 days [ATG], P .0001). The median time to an antigen specific response also occurred later in those
receiving Campath 1H (365 days [Campath 1H] versus 150 days [ATG], P  .004). There was no significant
difference between the 2 groups in terms of fungal or viral infections. Campath 1H is effective in decreasing the
incidence of GVHD without increasing the risk of relapse. Although there is a significant delay in immune
reconstitution, there was no increase in infectious complications or relapse in recipients of Campath 1H. Further
studies are warranted to assess if a lack of difference in infection rates are still demonstrated in larger cohorts.
© 2007 American Society for Blood and Marrow Transplantation
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Campath 1H 585NTRODUCTION
Graft-versus-host disease (GVHD) represents
ne of the major causes of morbidity and mortality
mong patients receiving a matched-unrelated or
ismatched-related hematopoietic stem cell trans-
lant (HSCT). At Childrens Hospital Los Angeles
CHLA), antithymocyte globulin (ATG) has been
sed as a standard part of our conditioning and
ost-HSCT prophylaxis of GVHD for patients re-
eiving a matched-unrelated HSCT (MUD) and a
ismatched-related HSCT. Pre-HSCT ATG has
een used to deplete the host’s immune system to
educe the risk of rejection. Post-HSCT ATG has
een used to decrease the donor T cells in vivo to
educe the risk of GVHD. Despite these measures, a
ajority of our MUD and mismatched-related pa-
ients develop clinically signiﬁcant GVHD.
Alemtuzumab (Campath 1H) is a humanized
onoclonal antibody to CD52, an antigen expressed
y T and B lymphocytes, eosinophils, monocytes, nat-
ral killer cells, and some antigen-presenting dendritic
ells [1]. The majority of CD34 stem cells and gran-
locytes are CD52 negative, and are therefore only
odestly affected by the use of Campath 1H [2,3].
ampath 1H given prior to transplantation remains
resent after the graft infusion and provides an in vivo
cell depletion resulting in a lower risk of acute
VHD a(GVHD) [4-6]. However, there has been a
igh incidence of adenoviral infections [7,8] and CMV
eactivation [9,10] associated with the use of Campath
able 1. Patient Characteristics
A
ales:Females
edian age at time of HSCT 7.4 yea
iagnosis
ALL
(Induction failure)
(CR2)
(CR3)
AML
(Induction failure)
(CR2)
CML (total)
(CP1)
(CP2)
SAA
ALD
CID
onditioning regimen
Busulfan/cytoxan
TBI/etoposide
Procarabazine/Cy/TLI
edian number of total nucleated cells (TNC)
infused/kg recipient body weight 5  108 TNC/
SCT indicates hematopoietic stem cell transplantation; ATG, a
myelogenous leukemia; CML, chronic myelogenous leukemia; S
immunodeﬁciency; TBI, total body irradiation; TLI, total lymphoid irH. Theoretically, in vivo T cell depletion of donor
rafts could lead to increased rates of leukemia re-
apse, from abrogation of the graft-versus-leukemia
ffect.
We replaced ATG with Campath 1H in patients
eceiving unrelated HSCT and mismatched-related
SCT to determine if we could decrease the inci-
ence of GVHD, without increasing the incidence of
iral and fungal infections or relapse.
ATIENTS AND METHODS
All patients who were scheduled to receive a
atched- or mismatched-unrelated or a mismatched-
elated bone marrow or peripheral blood HSCT be-
ween April 2004 and June 2006 at CHLA, were
ligible for this protocol. This study of the compari-
on of Campath 1H versus ATG was approved by the
hildrens Hospital Committee on Clinical Investiga-
ions (institutional review board). Consent was ob-
ained from the parents or the legal guardians and the
ubjects 18 years of age. Assent was obtained from
ubjects 7 years and 18 years of age. Patients who
eceived ATG for their GVHD prophylaxis between
anuary 2000 and March 2004 were used as historic
ontrols. Patients who received an unrelated umbilical
ord blood transplant were treated on a different pro-
ocol and were not eligible for this study.
Patient characteristics of study patients are shown in
able 1 and donor characteristics are shown in Table 2.
 13) Campath 1H (n  14)
9:5
-19 years) 13 years (3-17.8 years)
1
2
1
1
6
3
0
0
0
0
8
6
0
 108-11.6  108) 4.8  108 TNC/kg (2.3  108-38.6 108)
ocyte globulin; ALL, acute lymphoblastic leukemia; AML, acute
vere aplastic anemia; ALD, adrenoleukodystrophy; CID, combinedTG (n
9:4
rs (3.4
1
2
0
0
3
2
1
2
1
1
7
4
2
kg (1.4
ntithym
AA, seradiation; TNC, total nucleated cells.
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A. J. Shah et al.586onditioning Regimens and GVHD Prophylaxis
All patients received a myeloablative conditioning
egimen. The schematic diagram for the Campath 1H
atients is seen in Figure 1. Campath 1H patients
eceived a total of 52 mg/m2 divided over 3 days
re-HSCT (days 6, 4, and 2) and 2 doses post-
SCT of 10 mg/m2/dose on days 1 and 2. ATG
ecipients were given a regimen of ATGAM 20 mg/
g/dose for 4 doses pre-HSCT (days7,5,3, and
1) and 20 mg/kg/dose  5 doses post-HSCT (days
, 7, 9, 11, and 13). All patients on both the Campath
H and ATG arms received short course of metho-
rexate (10 mg/m2) post-HSCT on days 3, 6, 11, and
8. Some patients with transplant-related toxicity (ie,
able 2. Donor Characteristics
ATG
(n  13)
Campath 1H
(n  14)
one marrow/peripheral blood 12/1 13/1
LA antigen mismatch
0 12 10
1 1 3
2 0 1
onor type
Mismatched related 1 1
Matched unrelated 12 13
ex match
Male to male 5 7
Male to female 1 3
Female to male 3 3
Female to female 2 1
TG indicates antithymocyte globulin.
-2-3-4-5-6-7
Campath 1H
(52 mg/m2)
12.5 20 20 
Schema of Campath C
and Mismatc
-8
Standard Conditioning 
Regimen
igure 1. Schematic diagram of the protocol for Campath 1H admin
ransplant. The total dosage of Campath 1H given pre-HSCT w
0 mg/m2.enoocclusive disease (VOD) or severe mucositis) did
ot receive the 4th dose of MTX. All patients also
eceived tacrolimus post-HSCT for GVHD prophy-
axis. If patients were unable to tolerate tacrolimus,
hen they were changed to Cyclosporin A. aGVHD
as graded according to the Glucksberg scale [11].
ampath Levels
The basis for the determination of free Campath1H
evels is based on the speciﬁc binding of Campath 1H to
ormal human peripheral blood CD3 lymphocytes.
he concentration of free anti-CD52 antibody in patient
amples was determined by incubating heat-inactivated
atient serum with peripheral blood leukocytes from
ormal donors, followed by detection of Campath1H
ound to the cells using FITC-labeled secondary anti-
odies to the human Campath1H antibody (Figure 2).
ormal peripheral blood was collected in preservative-
ree heparin. The leukocytes were isolated on Ficoll-
ypaque gradients and suspended at 4 106 cells/mL
n phosphate-buffered saline. A total of 4  105 cells
0.1/mL) were added to 75-mm test tubes. Twenty
icroliters of patient serum to be tested or serial
ilutions of anti-CD52 antibody diluted in normal
erum to a ﬁnal concentration of 100, g/mL, 10
g/mL, and 1 g/mL to establish a standard curve
ere added to the test tubes. After incubation at 4°C
or 30 minutes, the leukocytes were washed and incu-
ated with FITC-labeled antihuman  and antihuman
light chains (Beckman-Coulter, Fullerton, CA) and
E-labeled murine antihuman CD3 antibody (Bec-
0 0221
CT
tioning For Unrelated 
elated HSCT
Tacrolimus
Campath 1H
(10 mg/m2)
3 6 11 18
MTX 10 mg/ m2
n to patients receiving a matched-unrelated or mismatched-related
g/m2. The total dosage of Campath 1H given post-HSCT was-1
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Campath 1H 587on-Dickinson, Mountain View, CA). After incuba-
ion at 4°C for 30 minutes, the cells were washed and
xed. The mean channel ﬂuorescence values for FITC
f the CD3-positive cells (PE-positive) stained with
he serial dilutions of Campath 1H were determined
nd a standard curve was generated; the cells stained
sing patient’s sera were assessed for mean ﬂuores-
ence for FITC of the CD3 cells, which were read
gainst the standard curve. The lower limit of detec-
ion of free antibody was 1 g/mL.
nfection Prophylaxis
All patients were housed in the bone marrow
ransplant unit with high-efﬁciency particulate air ﬁl-
ered rooms or laminar air ﬂow. All patients received
rophylactic antibiotic, antiviral, and antifungal ther-
py according to our institutional standard of care.
nfectious disease prophylaxis was the same for both
he ATG and Campath 1H patients. Prophylaxis with
anciclovir or foscarnet was given pre-HSCT and
fter engraftment to all patients who were cytomega-
ovirus (CMV) seropositive or whose donors were
MV seropositive. All patients were tested weekly
hile in the hospital for virus, fungi, and bacteria.
atients had cultures or polymerase chain reaction
PCR) assays of their blood, urine, and stool for CMV
nd adenovirus according to our standard operating
rocedures. Patients who developed symptoms of
ther viruses were tested for these by culture or PCR
f available. All patients received intravenous immu-
oglobulin therapy every 2 weeks while inpatients and
very 4 weeks as outpatients.
mmune Reconstitution
Cellular immunologic functions were determined
ollowing HSCT. Patient immune function was eval-
ated by determining the absolute numbers of T, B,
nd NK cells, phytohemagglutinin (PHA) responses
0
2
4
6
8
10
12
-3 -2 -1 0 1 2 3 4 5 6 8 10
Days (
Concentration 
of Campath 
( g/ ml) 
igure 2. Levels of Campath 1H in the serum. The X-axis shows
easured using the bioassasy in g/mL. None of the patients hadnd antigen-speciﬁc T-lymphocyte blastogenesis fol- powing speciﬁc antigenic stimulation (tetanus toxoid,
andida, CMV, herpes simplex virus, and varicella
oster virus) as previously described [12].
The presence of T cells was noted when a mini-
um of 30 CD3 T cells/mL were detected in the
eripheral blood. A PHA response was considered to
e positive when there was 75,000 cpm 3H-thymi-
ine incorporation. Positive antigen responses were
eﬁned as a 	 cpm 3000. Immune functions were
erformed weekly after patients engrafted until the
ate of discharge. After patients were discharged
ome, immune functions were performed every 3
onths.
tatistical Analysis
Results were analyzed as of November 25, 2006.
he primary endpoints of this study were the presence
f aGVHD and immune reconstitution. Secondary
ndpoints were infectious complications, relapse, and
verall survival.
Fisher’s exact test was used to compare categoric
ariables between groups (GVHD rates, infectious
omplications, relapse, and immune reconstitution).
roup comparisons were 2-sided with a type I error of
0.05. Because of the small sample sizes, we did not
ave enough power to detect small to moderate dif-
erences between the 2 groups. Event-free and overall
urvival, as well as time to T cell reconstitution, time
o PHA response, and time to antigen-speciﬁc re-
ponses were estimated using the method of Kaplan
nd Meier [13]. Estimates for each group are reported
long with 95% conﬁdence intervals. Breslow-Gehan-
ilcoxon tests were used to compare these time-
elated measures between groups.
ESULTS
Between May 2004 and May 2006, there were 14
14 15 16 18 19 20 22 23 24 25 27 28 34
d Post-Transplant)
UPN 826
UPN 828
UPN 832
UPN 836
UPN 839
UPN 850
UPN 855
UPN 863
UPN 875
UPN 877
UPN 895
UPN 903
UPN 908
ys post-HSCT and the Y-axis the concentration of Campath 1H
ble Campath 1H after 30 days post-HSCT.11 12 13
Pre- an
the daatients who received Campath 1H as part of their
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A. J. Shah et al.588onditioning regimen and subsequently received a
UD or mismatched-related HSCT. These patients
ere compared to a historic group of similar patients
ho received ATG (n 
 13) as part of their condition-
ng regimen. Characteristics of the patients (Table 1) and
heir donors (Table 2) as well as their conditioning
egimens were similar. The dose of total nucleated
ells (TNC) infused was similar between the 2 groups.
he 2 groups were then compared in terms of the
resence of severe aGVHD, infectious complications,
mmune reconstitution, relapse, and survival.
ampath 1H Levels
Campath 1H levels were determined on the ﬁrst
3 patients of this study (Figure 2). The 13 patients
leared Campath 1H at a median of 20 days post-
SCT (range: 11-28 days). No detectable (1 g/
L) Campath1H was seen in any of the remaining
atients after day 30 post-HSCT. The half-life of
ampath 1H was determined to be 5.36 days (2.4-6.3
ays), with a standard deviation of 1.2 days.
VHD
GVHD was evaluated in all recipients of unrelated
SCT. Severe aGVHD (deﬁned as grade III or IV
ccording to the Glucksberg scale) [11] was seen in 0
f 14 patients receiving Campath 1H compared to 6 of
3 patients who received ATG (P 
 .006). Two re-
ipients of Campath 1H developed mild (Grade 1)
kin GVHD, which was controlled with low-dose cor-
icosteroids. One of the 2 Campath patients who de-
eloped GVHD relapsed his disease (CML) 2 years
ost-HSCT. Of the 12 patients who did not develop
ny GVHD, 1 patient died of relapse of his primary
eukemia.
Of the 6 patients who received ATG and devel-
ped severe GVHD, all were subsequently treated
ith a combination of a calcineurin inhibitor, high-
ose steroids, and Daclizumab or other agents for
rolonged duration to control their GVHD. Five re-
ipients of ATG developed Grade 1-2 GVHD, which
as controlled with corticosteroids alone. Of the re-
aining 2 patients who did not develop any GVHD,
patient died of relapse of his primary leukemia.
Of the 14 patients who received Campath 1H, 8
atients are surviving. Of these patients, 1 patient has
able 3. Median Time to the Development of Speciﬁc Immune Respons
Ca
resence of >30 CD3 T cells/mm3 64.5 d
resence of normal PHA response (>75,000 cpm) 283 d
resence of antigen-specific responses ( 3000 cpm) 365 d
pm indicates counts per minute; ATG, antithymocyte globulin.xtensive chronic GVHD (cGVHD). This patient was toncompliant with her medications. Her GVHD is
ow under control with 3 immunosuppressive medi-
ations. Of the 13 patients who received ATG, 8
atients are surviving; 5 have extensive cGVHD and
emain on immunosuppression.
mmune Reconstitution
All patients were evaluated weekly after engraft-
ent for the development of T cells. Immune recon-
titution for patients receiving Campath 1H and ATG
re shown in Table 3. T cell reconstitution was de-
ned as the ﬁrst time point that patients had an abso-
ute number of 30 CD3 T cells/mm3 in the pe-
ipheral blood. Median time to T cell reconstitution
n the peripheral blood occurred later in the Campath
H group compared to the ATG group. For patients
eceiving Campath 1H, T cell reconstitution in the
eripheral blood occurred at a median of 64.5 days
ost-HSCT (range: 33-140 days, n 
 13). Patients
ho received ATG had T cell reconstitution in the
eripheral blood at a median of 27 days post-HSCT
18-68 days, n 
 13). The difference between the
imes to T cell reconstitution was statistically dif-
erent (Campath 1H; 64.5 days versus ATG: 27 days,

 .0014).
Median time to the development of normal PHA
esponses (75, 000 cpm) occurred later in the Cam-
ath 1H group compared to those who received ATG.
or patients receiving Campath 1H, normal PHA
esponses occurred at a median of 283 days (range:
48-420 days, n 
 7). Five patients in the Campath
H group died prior to the development of PHA
esponses. Two patients have not developed PHA
esponses at days 193 and 244 post-HSCT. Patients
ho received ATG had normal PHA responses at a
edian of 90 days post-HSCT (range: 46-216 days,

 11). Two patients died prior to the development
f PHA responses in the ATG group. The difference
etween the times to normal PHA responses was sta-
istically different (Campath 1H, 283 days versus
TG, 90 days, P 
 .0001).
Median time to the development of antigen-spe-
iﬁc responses also was later in the Campath 1H
roup compared to the ATG group. Recipients of
ampath 1H developed antigen speciﬁc responses at a
edian of 365 days (range: 225-425 days, n
 6). Prior
Conﬁdence Intervals)
1H (n  14) ATG (n  13) P Value
, 100) (n  13) 27 days (23, 48) (n  13) .0014
0, 420) (n  7) 88 days (52, 120) (n  11) .0001
5, 420) (n  6) 150 days (90, 180) (n  11) .0037e (95%
mpath
ays (42
ays (24
ays (36o developing antigen speciﬁc responses in the Cam-
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Campath 1H 589ath 1H group, 5 patients died, 1 patient relapsed, and
patients are still awaiting antigen-speciﬁc responses
days 193, 244, and 492 post-HSCT). Patients who
eceived ATG had antigen-speciﬁc responses at a me-
ian of 150 days post-HSCT (range: 88-840 days, n

1). Prior to development of antigen-speciﬁc re-
ponses in the ATG group, 2 patients died. The dif-
erence between the times to antigen-speciﬁc re-
ponses was statistically different (Campath 1H, 365
ays, versus ATG, 150 days, P 
 .004).
nfectious Complications
All patients were analyzed for the development of
iral and fungal disease for 1-year post-HSCT. All
atients had quantitative testing for CMV weekly.
ther viruses were tested quantitatively if symptoms
ere present. Human herpes virus (HHV)-6 was not
ested routinely prior to 2005. Table 4 shows the
rganisms that were isolated. There were no signiﬁ-
ant differences between Campath 1H and ATG for
he numbers of organisms isolated (Campath 1H, 21
otal infections versus ATG, 18 total infections). It
hould be noted that there was not enough power to
etect small to moderate differences between the 2
roups. However, when examining the patients who
eveloped speciﬁc infections, there were higher abso-
ute numbers of patients who developed CMV,
HV6, or BK virus among the patients who received
ampath 1H compared to those who received ATG (4
MV, 3 HHV6, 4 BK virus [Campath 1H] versus 1
MV, 0 HHV6, and 0 BK virus [ATG]). The patients
ho developed HHV6 had symptoms of HHV6
nfection (pulmonary symptoms [n 
 1] and bone
arrow suppression [n 
 2]). Three of the 4 pa-
ients who had BK virus had the presence of hem-
rrhagic cystitis. Patients who received ATG had
able 4. Fungal and Viral Infections Among Patients
ATG
(n  13)
Campath 1H
(n  14) P Value
denovirus 6 5 .77
K virus 0 4 .1
MV 1 4 .33
andida 6 2 .1
(blood/urine/stool) 2/1/3 0/0/2
BV 1 0 .48
HV6 0 3 .22
SV 2 0 .22
nfluenza 1 0 .48
arainfluenza 0 1 1.00
otavirus 0 1 1.00
SV 1 0 .48
oxoplasmosis 0 1 1.00
otal infections 18 21
TG indicates antithymocyte globulin; HSV, herpes simplex virus;
CMV, cytomegalovirus; EBV, Epstein-Barr virus; HSV, herpes
simplex virus; RSV, respiratory syncytial virus.ore absolute numbers of candidal infections (Campath 1H [n 
 2] versus ATG [n 
 6], P 
 .1)
ompared to the patients who received Campath
H. All patients received ﬂuconazole prophylaxis,
nless they were treated for presumed fungal infec-
ion prior to HSCT with alternate antifungal infec-
ions. There was 1 death resulting from infection in
ach group: Campath 1H (1 Toxoplasmosis-related
eath) versus ATG (1 Epstein-Barr virus [EBV]-
elated death).
ngraftment and Relapse
All patients in both the Campath 1H group and
he ATG group engrafted. In the Campath 1H group,
patient has mixed chimerism (65% donor engrafted)
nd requires periodic blood and platelet transfusions.
Patients with a malignant disease were also evalu-
ted for relapse. Of the 14 patients with leukemia who
eceived Campath 1H, 2 patients relapsed (14%); of
he 9 patients with leukemia who received ATG, 4
atients relapsed (44%) (P 
 .16). Of the 2 patients
ho received Campath 1H and relapsed, 1 died of
rogressive disease and the other is alive. All patients
ho relapsed post-HSCT in the ATG group have
ied of progressive disease.
urvival
Kaplan-Meier overall and event-free survival
urves are shown in Figure 3A and B. The median
ollow-up for patients receiving Campath 1H is 674
ays (range: 193-921 days). The median follow up for
atients receiving ATG is 1656 days (range: 818-2390
ays).
All patients were observed for at least 180 days.
he Kaplan-Meier curves were comparable for overall
urvival (Wilcoxon P 
 .36) and event-free survival
Wilcoxon P 
 .4). The event-free survival for pa-
ients receiving Campath 1H at 100 days, 180 days,
nd 1 year was 79%, 71%, and 63%. The event-free
urvival for patients receiving ATG at 100 days, 180
ays, and 1 year was 85%, 77%, and 69%.
The overall survival at 100 days, 180 days, and 1
ear for patients receiving Campath 1H was 79%,
1%, and 63%. The overall survival at 100 days, 180
ays, and 1 year for patients receiving ATG was 92%,
5%, and 69%. At 100 days, the proportion still alive
id not differ signiﬁcantly between the groups (79%
or Campath versus 92% for ATG, Fisher’s exact test

 .60), nor did the event-free proportion (79% for
ampath versus 85% for ATG, Fisher’s exact test P

.00).
Causes of death in the Campath 1H group in-
luded: relapse (n 
 1), toxoplasmosis (n 
 1),
eukoencephalopathy (n 
 1), VOD (n 
 1), intra-
ranial hemorrhage (n 
 1), and cardiac failure
n 
 1). Causes of death in the ATG group in-
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A. J. Shah et al.590luded: relapse (n 
 4) and EBV-related lympho-
roliferative disease (n 
 1).
ISCUSSION
Despite prophylactic measures, GVHD remains a
igure 3. (A) Event-free survival of patients in the Campath 1H ve
here was no signiﬁcant difference in the event-free survival be
atients in the Campath 1H versus ATG groups. There was n
Wilcoxon P-value 
 .36).igniﬁcant cause of morbidity and mortality among Fecipients of matched-unrelated and mismatched-
elated HSCT. Once GVHD occurs, the treatment
emains unsatisfactory. Corticosteroids have been a
rimary treatment for aGVHD [14]. Treatment with
orticosteroids have given a durable response in
50% of patients receiving unrelated HSCT [15,16].
G groups. Patients were censored for death, relapse, or rejection.
the 2 groups (Wilcoxon P-value 
 .40). (B) Overall survival of
iﬁcant difference in the overall survival between the 2 groupsrsus AT
tween
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Campath 1H 591re a variety of new agents that have been used, with
ess than optimal results. Although these newer ther-
pies (eg, daclizumab [17], denileukin diftitox [18],
nd pentostatin [19]) have treated GVHD, there were
ften increased opportunistic infections that resulted
n mortality.
The purpose of this pilot pediatric study was to
etermine if Campath 1H was able to decrease the
ncidence of GHVD without increasing infections or
elapse. With the use of Campath 1H, the incidence of
evere GVHD was signiﬁcantly lower compared to
hose who received our previous regimen using ATG.
n addition our patients received 2 doses (10 mg/m2)
n days 1 and 2. Using a bioassay to detect Campath
H in the patient serum, we were able to detect the
resence of circulating Campath 1H at the time of
ransplantation and remaining until 30 days post-
SCT. This may have resulted in a degree of in vivo
cell depletion that was able to minimize extensive
GVHD. Ongoing evaluations will determine whether
here will be any difference in cGVHD compared to
ur historic controls.
Previous studies have shown that T cell-depleted
ransplants result in higher relapse rates [20]. In our
tudy, we did not observe an increase in relapse. How-
ver, this statement should be taken with caution,
ecause the follow-up on the Campath 1H patients
as lower than that of the patients receiving ATG.
onger follow-up is needed before we can ascertain
hether Campath 1H does not have an impact on
elapse.
Compared to the patients receiving ATG, there
as a signiﬁcant delay in immune reconstitution in
atients who received Campath 1H. This is similar to
he adult trials where median time to T cell recovery
as also delayed [8,9]. To our knowledge, our study is
he ﬁrst to evaluate the immune reconstitution in a
ediatric only population. The prolonged immuno-
uppression seen in patients receiving Campath 1H
id not result in an increase in viral or fungal infec-
ions compared to recipients of ATG. This is in con-
rast with other studies that showed in increase in
nfections, especially CMV and adenovirus [7-10].
MV has been a known complication among patients
eceiving Campath 1H [8,9]. At our institution, test-
ng for CMV was the same from 2002-2006, spanning
he times for both the ATG and the Campath 1H
roups. One of the major differences between our
tudy and that of others is the aggressive anti-CMV
rophylaxis used at our institution. At CHLA, patients
ho are CMV seropositive or have a donor who is
MV seropositive are given gancyclovir pre- and
ost-HSCT. In previous studies, that showed an in-
rease in CMV infections, patients were given antivi-
al therapy only if 2 consecutive qualitative CMV
CR assays were positive [9,10]. Recent reports have
hown that pre- and posttransplant gancylcovir re- Huces the incidence of CMV infections after Campath
H-based conditioning [21]. Our study is in support
f the more aggressive use of prophylaxis to decrease
he incidence of CMV infections in Campath 1H-
ased conditioning regimens.
Our study did show an increase in the absolute
umbers of Campath 1H recipients developing certain
iral infections (CMV, HHV6, and BK virus). One
ossible explanation for the increase in HHV6 and BK
irus may be the more recent increase in routine
esting for these speciﬁc viruses. Testing for HHV6
ecame more frequent at our institution after 2005.
ecause it is known that the anti-CD3 monoclonal
ntibody treatment administered as a prophylaxis for
VHD also increases the risk of HHV6 infections
22], we began more frequent testing for HHV6 after
sing Campath 1H in our conditioning regimen. Ap-
roximately 40% of HSCT recipients develop an
HV6 infection within 2-4 weeks post-HSCT [23].
herefore, we do not know if the increase in absolute
umbers of HHV6 infections represented a true in-
rease in the numbers of patients or if this is increase
esulted from more frequent testing for this virus.
BK viruria occurs in nearly all HSCT recipients
ut has a low predictive value for the development of
K viremia [24-26]. In general, the incidence of BK
irus in recipients of pediatric HSCT recipients is
nknown. We began routinely testing for BK virus in
004. Of the patients who were found to have BK
irus, 3 had hematuria and 1 was asymptomatic. Be-
ause patients receiving the ATG regimen were not
ested as often for polyoma virus, it is unclear if there
ere previous patients who also had polyoma virus but
ere asymptomatic.
The numbers of infection-related deaths in our
tudy were not signiﬁcantly different between the pa-
ients given ATG or Campath 1H. Possible explana-
ion for this observation is that patients given Cam-
ath 1H did not develop GVHD following viral
isease. It is possible that the infections in the Cam-
ath 1H recipients did not trigger an increase in
VHD because of the patient’s relative T cell deﬁ-
iency, thus allowing for the effective treatment of
nfections in the Campath 1H group without the need
o simultaneously increase the intensity of immune
uppression.
One of the limitations of this study is the small
umbers of pediatric patients compared to most larger
dult studies. Larger pediatric cooperative group trials
sing Campath 1H for unrelated HSCT, will provide
ore information about its potential efﬁcacy in de-
reasing GVHD without increasing infections or re-
apse. A second limitation of this study is the shorter
ollow-up seen in the patients with Campath 1H com-
ared to our historic control. Longer follow-up is
eeded to assess the role of Campath 1H in pediatric
SCT.
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A. J. Shah et al.592In this pilot study, the recipients of Campath 1H
nd ATG had similar outcomes in terms of infections,
elapse, and overall survival. Recipients of Campath
H did have a signiﬁcant delay in immune reconsti-
ution. CD52 is present on the common lymphoid
rogenitor (G. Crooks, unpublished observation) and
ampath 1H may decrease the numbers of this pro-
enitor population that engraft and proliferate to ef-
ect early immune reconstitution.
In conclusion, Campath 1H is an effective means to
ecrease the incidence of aGVHD. Campath 1H has
hanged the clinical course of our patients undergoing
nrelated donor and mismatched-related HSCT by
ompletely eliminating serious aGVHD. With proactive
se of monitoring and prophylactic antivirals, antifun-
als, and antibacterials, the numbers of viral or fungal
nfections were not signiﬁcantly increased in our study
roup compared to our historic control. Because of the
bservation of delayed immune reconstitution after
ampath 1H, further studies will be aimed at decreasing
he dosages of Campath1H without increasing the inci-
ence of GVHD.
CKNOWLEDGMENTS
This work was supported in part by the National
nstitutes of Health NCRR General Clinical Research
enter (GCRC) Grant MO1 RR00043, and was per-
ormed at the GCRC at Childrens Hospital Los An-
eles. Computational assistance was provided by the
ational Institutes of Health NCRR GCRC MO1
R00043, CDMAS Project, and was performed at the
CRC at Childrens Hospital Los Angeles. The
uthors would like to thank Matthew Permuy and
dward Cosme for their technical assistance and Col-
een Azen for statistical analysis. Most of all, we
ould like to thank the patients and their families
or the participation in this study and the nursing
taff of the Childrens Hospital Los Angeles Bone
arrow Transplant Unit for their tireless commit-
ent to these patients.
EFERENCES
1. Buggins AGS, Mufti GJ, Salisbury J, et al. Peripheral blood but
not tissue dendritic cells express CD52 and are depleted by
treatment with alemtuzumab. Blood. 2002;100:1715-1720.
2. Gilleece MH, Dexter TM. Effect of Campath 1-H antibody on
human hematopoietic progenitors in vitro. Blood. 1993;82:
807-812.
3. Williams RJ, Clarke E, Blair A, et al. Impact on T cell depletion
and CD34cell recovery using humanized C52 monoclonal
antibody (CAMPATH 1H) in BM and PBSC collections: com-
parison with CAMPATH 1M and CAMPATH 1G. Cyto-
therapy. 2000;2:5-14.
4. Hale G, Jacobs P, Wood L, et al. CD52 Antibodies for pre-
vention of graft versus host disease and graft rejection followingtransplantation of allogeneic peripheral blood stem cells. BMT.
2000;26:69-76.
5. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo Campath
1H prevents graft versus host disease following nonmyeloabla-
tive stem cell transplantation. Blood. 2000;96:2419-2425.
6. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplan-
tation-related mortality following unrelated donor stem cell
transplantation by using nonmyeloablative conditioning regi-
men. Blood. 2002;99:1071-1078.
7. Myers GD, Kranes RA, Weiss H, et al. Adenovirus infection
rates in pediatric recipients of alternate donor allogeneic bone
marrow transplants receiving either antithymocyte globulin
(ATG) or alemtuzumab (Campath). Bone Marrow Transplant.
2005;36:1001-1008.
8. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infec-
tions following allogeneic stem cell transplantation: incidence
and outcome in relation to graft manipulation, immunosup-
pression, and immune recovery. Blood. 2002;100:1619-1627.
9. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence
of cytomegalovirus infection after nonmyeloablative stem cell
transplantation: potential role of Campath-1H in delaying im-
mune reconstitution. Blood. 2002;99:4357-4363.
0. Chakraverty R, Robinson S, Peggs K, et al. Excessive T cell
depletion of peripheral blood stem cells has an adverse effect
upon outcome following allogeneic stem cell transplantation.
Bone Marrow Transplant. 2001;28:827-834.
1. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of
graft versus host disease in human recipients of marrow fromHLA
matched sibling donors. Transplantation. 1974;18:295-304.
2. Weinberg K, Hershﬁeld MS, Bastian J, et al. T lymphocyte
ontogeny in adenosine deaminase-deﬁcient severe combined
immune deﬁciency after treatment with polyethylene modiﬁed
adenosine deaminase. J Clin Invest. 1993;92:586-602.
3. Kaplan E, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc. 1958;135:185.
4. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of
therapy for acute graft versus host disease: initial treatment.
Blood. 1990;76:1464-1472.
5. Roy J, McGlave PB, Filopovich AH, et al. Acute graft versus
host disease following unrelated donor marrow transplantation:
failure of conventional therapy. Bone Marrow Transplant. 1992;
10:77-82.
6. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/
severe acute GVHD after allogeneic bone marrow transplan-
tation: an analysis of clinical risk features and outcome. Blood.
1990;75:1024-1030.
7. Lee SJ, Zahrieh D, Agoura E, et al. Effect of up-front Dacli-
zumab when combined with steroids for the treatment of acute
graft vs. host disease: results of a randomized trial. Blood. 2004;
104:1559-1564.
8. Ho V, Zahrieh D, Hochberg E, et al. Safety and efﬁcacy of
denileukin diftitox in patients with steroids refractory acute
graft versus host disease after allogeneic hematopoietic stem
cell transplantation. Blood. 2004;104:1224-1226.
9. Bolanos-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin
in steroid-refractory acute graft-versus-host disease. J Clin
Oncol. 2005;23:2661-2668.
0. Apperley JF, Jones L, Hale G, et al. Bone marrow transplan-
tation for patients with chronic myeloid leukemia: T cell de-
pletion with Campath-1 reduces the incidence of graft versus
host disease but may increase the risk of leukaemic relapse. Bone
Marrow Transplant. 1986;1:53-66.
22
2
2
2
2
Campath 1H 5931. Kline J, Pollyea DA, Stock W, et al. Pre-transplant ganciclovir
and post transplant high dose valacyclovir reduce CMV infec-
tions after alemtuzumab-based conditioning. Bone Marrow
Transplant. 2006;37:307-310.
2. Zerr DM, Gooley TA, Yeung L, et al. Human herpersvirus 6
reactivation and encephalitis in allogeneic bone marrow trans-
plant recipients. Clin Infect Dis. 2001;34:309-317.
3. Yoshikawa T, Asano Y, Ihira M, et al. Human herpesvirus 6
viremia in bone marrow transplant recipients: clinical features
and risk factors. J Infec Dis. 2002;185:847-853.4. Leung AY, Suen CK, Lie AK, et al. Quantiﬁcation of polyoma
BK virus in hemorrhagic cystitis complicating bone marrow
transplantation. Blood. 2001;98:1971-1978.
5. Arthur RR, Shah KV, Baust SJ, et al. Association of BK viruria
with hemorrhagic cystitis in recipients of bone marrow trans-
plants. N Eng J Med. 1986;315:230-234.
6. Apperley JF, Rice SJ, Bishop JA. Late onset hemorrhagic
cystitis associated with urinary excretion of polyomaviruses
after bone marrow transplantation. Transplantation. 1987;43:
108-112.
